NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.)

NBIXのニュース

   Neurocrine Biosciences cut to neutral at Piper on growth trajectory of Ingrezza  2022/03/03 20:23:48 Seeking Alpha
Piper Sandler has downgraded Neurocrine Biosciences (NBIX) to neutral from overweight amid concerns of more modest long-term growth of its tardive dyskinesia treatment Ingrezza.
   Where Neurocrine Biosciences Stands With Analysts  2022/02/25 19:05:22 Benzinga
Neurocrine Biosciences (NASDAQ: NBIX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 2 0 0 2M Ago 0 1 2 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $110.75 with a high of $154.00 and a low of $90.00. Below is a summary of how these 8 analysts rated Neurocrine Biosciences over the past … Full story available on Benzinga.com
   Neurocrine Biosciences upgraded to buy at Goldman Sachs; sees 32% upside (NBIX)  2022/02/25 16:34:26 Seeking Alpha
Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months.
   Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript  2022/02/11 21:30:47 The Motley Fool
NBIX earnings call for the period ending December 31, 2021.
   Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript  2022/02/11 18:19:04 Seeking Alpha
   Neurocrine Biosciences cut to neutral at Piper on growth trajectory of Ingrezza  2022/03/03 20:23:48 Seeking Alpha
Piper Sandler has downgraded Neurocrine Biosciences (NBIX) to neutral from overweight amid concerns of more modest long-term growth of its tardive dyskinesia treatment Ingrezza.
   Where Neurocrine Biosciences Stands With Analysts  2022/02/25 19:05:22 Benzinga
Neurocrine Biosciences (NASDAQ: NBIX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 2 0 0 2M Ago 0 1 2 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $110.75 with a high of $154.00 and a low of $90.00. Below is a summary of how these 8 analysts rated Neurocrine Biosciences over the past … Full story available on Benzinga.com
   Neurocrine Biosciences upgraded to buy at Goldman Sachs; sees 32% upside (NBIX)  2022/02/25 16:34:26 Seeking Alpha
Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months.
   Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript  2022/02/11 21:30:47 The Motley Fool
NBIX earnings call for the period ending December 31, 2021.
   Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript  2022/02/11 18:19:04 Seeking Alpha
   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2021/09/02 20:13:00 Neurocrine Biosciences
SAN DIEGO , Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences: Kevin Gorman , Chief Executive Officer, will present at the Morgan Stanley 19 th Annual
   The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma  2021/08/12 12:09:26 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI ) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) Aptose Biosciences Inc.
   Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound  2021/08/11 14:00:00 Seeking Alpha
   Neurocrine Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/04 08:41:34 Seeking Alpha
   Neurocrine Biosciences EPS misses by $0.13, beats on revenue  2021/08/03 20:04:09 Seeking Alpha

calendar